Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance miglustat after switch from enzyme replacement therapy in adult type 1 Gaucher disease
2005-001651-37Phase 4Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of miglustat in Gaucher disease type 1 (GD1), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Percent change from baseline to Month 24 in liver volume. Started Oct 2005; status: completed.
02
Drugs
miglustat
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on 2005-001651-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001651-37.